The increased tumor-infiltration of Vγ9Vδ2 T-cells achieved by NZ should be considered as the starting point for designing new strategies of adoptive immune-therapy for osteosarcoma, as already experimented in clinical trials for other tumors [56], in particular, if refractory to the anti-tumor immune activity of CD8+T-lymphocytes. Here, CD8A is linked to osteosarcoma.